Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Tazoral "not approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Allergan will continue seeking a psoriasis indication for its oral tazarotene product Tazoral, the firm says following FDA's Sept. 24 "not approvable" letter. Among the "non-approvability issues" are the needs for a non-inferiority trial in severe psoriasis, an "acceptable" risk management plan and manufacturing deficiencies. Allergan "will work with the FDA to clarify" the request for a non-inferiority trial. The firm says it is "in the process of developing an appropriate risk mangement plan." The manufacturing issue "is either resolved or will be resolved shortly to the FDA's satisfaction," Allergan says. FDA's Dermatologic & Ophthalmic Drugs/Drug Safety & Risk Management advisory committees said that the Tazoral risk management plan was inadequate during a July 12 joint meeting...

Related Content

Topics

UsernamePublicRestriction

Register

PS002659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel